GSK will develop hepatitis C drugs with Regulus

02/25/2010 | Atlanta Journal-Constitution, The

GlaxoSmithKline and Regulus Therapeutics agreed to co-develop treatments for hepatitis C, extending a pact that started in microRNA treatments for inflammatory diseases. The deal entitles Regulus to potentially receive more than $150 million, plus royalties.

View Full Article in:

Atlanta Journal-Constitution, The